Somatostatin and Its Drug Derivatives Inhibit Alzheimer's Amyloid-Beta Aggregation
Somatostatin outperformed its marketed derivatives octreotide and lanreotide in inhibiting Aβ42 amyloid aggregation, achieving 91% inhibition at 25 μM.
Quick Facts
What This Study Found
Somatostatin inhibited Aβ42 fibrillogenesis by 91% at 25 μM, outperforming its derivatives octreotide and lanreotide as well as the reference inhibitor orange G (86%).
Key Numbers
Somatostatin: 91% Abeta42 fibrillogenesis inhibition at 25 mcM. d-Trp8-somatostatin: 74%. Octreotide and lanreotide: ~54%. Reference agent orange G: 86%. Tested at 1, 5, 10, and 25 mcM.
How They Did This
In vitro study testing somatostatin, d-Trp8-somatostatin, octreotide, and lanreotide on Aβ42 aggregation kinetics and cytotoxicity in mouse hippocampal HT22 cells.
Why This Research Matters
If somatostatin-based peptides can prevent amyloid aggregation, they could represent a new therapeutic approach for Alzheimer's disease using compounds already in clinical use for other conditions.
The Bigger Picture
Repurposing existing peptide drugs for Alzheimer's could accelerate treatment development since safety profiles are already established.
What This Study Doesn't Tell Us
In vitro study — Aβ42 aggregation inhibition in a test tube does not guarantee brain delivery or clinical efficacy. Somatostatin does not easily cross the blood-brain barrier.
Questions This Raises
- ?Can somatostatin or its derivatives be delivered to the brain effectively enough to inhibit amyloid aggregation in vivo?
- ?What is the mechanism of somatostatin's anti-aggregation effect?
Trust & Context
- Key Stat:
- 91% aggregation inhibition Somatostatin outperformed all other cyclic peptides and the reference compound in blocking Aβ42 fibril formation
- Evidence Grade:
- In vitro study — strong anti-aggregation data but clinical applicability depends on solving brain delivery challenges.
- Study Age:
- Published in 2025, contributing to the search for peptide-based Alzheimer's treatments.
- Original Title:
- Investigating the Interactions of a Cyclic Peptide Hormone Somatostatin and Its Derivatives on Amyloid-Beta Aggregation.
- Published In:
- ACS chemical neuroscience, 16(16), 3115-3126 (2025)
- Authors:
- Pham, Amy Trinh, Zhao, Yusheng, Oo, Amy, Hefny, Ahmed A, Ganesan, Aravindhan, Rao, Praveen P N
- Database ID:
- RPEP-13042
Evidence Hierarchy
Frequently Asked Questions
Could somatostatin drugs help with Alzheimer's?
In the lab, somatostatin strongly prevents the clumping of amyloid-beta proteins that characterizes Alzheimer's disease. However, getting enough drug into the brain to have this effect remains a major challenge that must be solved before clinical use.
What is amyloid-beta aggregation?
In Alzheimer's disease, a protein called amyloid-beta (Aβ42) clumps together into toxic fibrils and plaques that damage brain cells. Preventing this aggregation is one of the main therapeutic strategies being pursued for Alzheimer's.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13042APA
Pham, Amy Trinh; Zhao, Yusheng; Oo, Amy; Hefny, Ahmed A; Ganesan, Aravindhan; Rao, Praveen P N. (2025). Investigating the Interactions of a Cyclic Peptide Hormone Somatostatin and Its Derivatives on Amyloid-Beta Aggregation.. ACS chemical neuroscience, 16(16), 3115-3126. https://doi.org/10.1021/acschemneuro.5c00044
MLA
Pham, Amy Trinh, et al. "Investigating the Interactions of a Cyclic Peptide Hormone Somatostatin and Its Derivatives on Amyloid-Beta Aggregation.." ACS chemical neuroscience, 2025. https://doi.org/10.1021/acschemneuro.5c00044
RethinkPeptides
RethinkPeptides Research Database. "Investigating the Interactions of a Cyclic Peptide Hormone S..." RPEP-13042. Retrieved from https://rethinkpeptides.com/research/pham-2025-investigating-the-interactions-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.